Bayer boosts cell therapy pipeline with BlueRock acquisitionBayer has announced it is fully acquiring US cell therapy biotech BlueRock Therapeutics, whose cell therapy pipeline includes Share XBayer boosts cell therapy pipeline with BlueRock acquisitionhttps://pharmaphorum.com/news/bayer-boosts-cell-therapy-pipeline-with-bluerock-acquisition/
Finding the right reimbursement model for gene therapiesWith cell and gene therapies growing more and more important to healthcare, we sat down with Debbie Warner, Share XFinding the right reimbursement model for gene therapieshttps://pharmaphorum.com/views-and-analysis/finding-the-right-reimbursement-model-for-gene-therapies/
Former Alexion CEO Hallal makes comeback at cell therapy holding firm ElevateBioMassachusetts holding company ElevateBio has launched with $150m in initial funding from a range of investors on a Share XFormer Alexion CEO Hallal makes comeback at cell therapy holding firm ElevateBiohttps://pharmaphorum.com/news/former-alexion-ceo-hallal-makes-comeback-at-cell-therapy-holding-firm-elevatebio/
Mesoblast poised to file cell therapy for GVHD in USAustralian biotech Mesoblast can go ahead with a US filing for its off-the-shelf stem cell therapy for acute Share XMesoblast poised to file cell therapy for GVHD in UShttps://pharmaphorum.com/news/mesoblast-cell-therapy-gvhd-fda/
Cell Mogrify gets £420k funding for regenerative cell therapiesUK cell therapy company Cell Mogrify has been awarded £420,000 funding from Innovate UK to accelerate its data-driven Share XCell Mogrify gets £420k funding for regenerative cell therapieshttps://pharmaphorum.com/news/cell-mogrify-gets-420k-funding-for-regenerative-cell-therapies/
Will cell and gene therapies disrupt reimbursement?Cell and gene therapies could prove disruptive in terms of the life-changing benefits they could bring to people Share XWill cell and gene therapies disrupt reimbursement?https://deep-dive.pharmaphorum.com/magazine/disruptive-technologies/will-cell-and-gene-therapies-disrupt-drug-reimbursement/
Nearly 300 gene and cell therapies in development – reportPharma is becoming increasingly focused on gene and cell therapies, with nearly 300 in clinical development or awaiting Share XNearly 300 gene and cell therapies in development – reporthttps://pharmaphorum.com/news/nearly-300-gene-and-cell-therapies-in-development-report/
Roche and SQZ expand cell therapy deal to more than $1.3bnUS biotech SQZ Biotechnologies has expanded a collaboration with Roche to develop cancer therapies based on antigen presenting Share XRoche and SQZ expand cell therapy deal to more than $1.3bnhttps://pharmaphorum.com/news/roche-and-sqz-expand-cell-therapy-deal-to-more-than-1-3bn/
Gilead signs biotech deal arming T-cells to attack solid tumoursGilead’s Kite unit has signed a deal with the biotech HiFiBiO (High Fidelity Biology) to discover T-cell receptors Share XGilead signs biotech deal arming T-cells to attack solid tumourshttps://pharmaphorum.com/news/gilead-signs-biotech-deal-arming-t-cells-to-attack-solid-tumours/
